CHAPTER 13: The Application of Lipid Nanoparticles for Retinal Degenerative Diseases
Published:13 Sep 2018
R. V. S. Rajala, A. Rajala, and Y. Wang, in Therapies for Retinal Degeneration: Targeting Common Processes, ed. E. J. de la Rosa and T. G. Cotter, The Royal Society of Chemistry, 2018, pp. 216-229.
Download citation file:
Several nanotechnology podiums have gained remarkable attention in the area of medical sciences, including diagnostics and treatment. In the past decade, engineered multifunctional nanoparticles have served as drug and gene carriers. The most important aspect of translating nanoparticles from the bench to bedside is safety. These nanoparticles should not elicit any immune response and should not be toxic to humans or the environment. Lipid-based nanoparticles have been shown to be the least toxic for in vivo applications, and significant progress has been made in gene and drug delivery employing lipid-based nanoassemblies. There are several excellent reviews and reports on the general use and application of lipid-based nanoparticles; our review focuses on the application of lipid-based nanoparticles for the treatment of ocular diseases, and recent advances in and updates on their use.